Lupoli Roberta, Ciciola Paola, Costabile Giuseppina, Giacco Rosalba, Minno Matteo Nicola Dario Di, Capaldo Brunella
Department of Molecular Medicine and Medical Biotechnology, Federico II University, 80131 Naples, Italy.
Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy.
J Clin Med. 2020 Jan 22;9(2):313. doi: 10.3390/jcm9020313.
: Growing evidence shows that grape polyphenols can improve cardiovascular risk factors. Although there are clear data supporting a beneficial effect of grape supplementation on blood pressure and glucose metabolism, the effects of grape polyphenols on lipid metabolism are still controversial. : We performed a meta-analysis of randomized controlled trials (RCTs) to assess the effect of grape products on lipid profile. : A systematic search was performed in the PubMed, Web of Science, Scopus, and EMBASE databases without any language or publication year restriction. The reference lists of all retrieved articles were manually reviewed. RCTs evaluating the impact of grape products/juice/extracts on lipid profile were included. Difference in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), oxidized low-density lipoprotein cholesterol (oxLDL-C), apolipoprotein (apo) A, apo B before and after administration of grape products or placebo were expressed as mean differences (MD) with pertinent 95% confidence intervals (95% CI). The impact of clinical and demographic features on effect size was assessed by meta-regression. : The administration of grape products is associated with a significant improvement of lipid profile, as evidenced by changes in TC (MD: -7.6 mg/dL (-0.2 mmol/L); 95% CI: -10.8, -4.4; < 0.001), HDL-C (MD: 1.4 mg/dL (0.04 mmol/L); 95% CI: 0.8, 1.9; < 0.001, I = 74.7%, < 0.001), LDL-C (-6.3 mg/dL (-0.16 mmol/L); 95% CI: -9.5, -3.0; < 0.001), oxLDL-C (MD: -4.5 U/L; 95% CI: -7.5, -1.5; = 0.003, I = 90.6%, < 0.001), apo B (MD: -2.4 mg/dL (-0.05 µmol/L); 95% CI: -4.5, -0.3; p = 0.026), and TG (MD: -14.5 mg/dL (-0.16 mmol/L); 95% CI: -17.7, -11.2; < 0.001) levels in subjects receiving grape products compared to placebo. With regard to the extent of the lipid-lowering effect, compared to baseline values, the highest reduction was reported for LDL-C (MD: -5.6 mg/dL (-0.14 mmol/L); 95% CI: -9.5, -1.7; = 0.005) and for oxLDL-C (MD: -5.0 U/L; 95% CI: -8.8, -1.2; = 0.010, I = 0%, = 0.470). : Grape polyphenols exert a favorable effect on lipid profile in humans by significantly reducing plasma levels of LDL-C and oxLDL-C.
越来越多的证据表明，葡萄多酚可以改善心血管危险因素。尽管有明确的数据支持补充葡萄对血压和葡萄糖代谢有有益作用，但葡萄多酚对脂质代谢的影响仍存在争议。
我们对随机对照试验（RCT）进行了荟萃分析，以评估葡萄产品对血脂的影响。
在PubMed、科学网、Scopus和EMBASE数据库中进行了系统检索，没有任何语言或出版年份限制。对所有检索到的文章的参考文献列表进行了人工审查。纳入了评估葡萄产品/果汁/提取物对血脂影响的随机对照试验。葡萄产品或安慰剂给药前后总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、甘油三酯（TG）、氧化低密度脂蛋白胆固醇（oxLDL-C）、载脂蛋白（apo）A、apo B的差异以平均差异（MD）和相关的95%置信区间（95%CI）表示。通过荟萃回归评估临床和人口统计学特征对效应大小的影响。
与安慰剂相比，接受葡萄产品的受试者的TC（MD：-7.6mg/dL（-0.2mmol/L）；95%CI：-10.8，-4.4；P<0.001）、HDL-C（MD：1.4mg/dL（0.04mmol/L）；95%CI：0.8，1.9；P<0.001，I²=74.7%，P<0.001）、LDL-C（-6.3mg/dL（-0.16mmol/L）；95%CI：-9.5，-3.0；P<0.001）、oxLDL-C（MD：-4.5U/L；95%CI：-7.5，-1.5；P=0.003，I²=90.6%，P<0.001）、apo B（MD：-2.4mg/dL（-0.05µmol/L）；95%CI：-4.5，-0.3；P=0.026）和TG（MD：-14.5mg/dL（-0.16mmol/L）；95%CI：-17.7，-11.2；P<0.001）水平的变化表明，葡萄产品的给药与血脂谱的显著改善有关。关于降脂效果的程度，与基线值相比，LDL-C（MD：-5.6mg/dL（-0.14mmol/L）；95%CI：-9.5，-1.7；P=0.005）和oxLDL-C（MD：-5.0U/L；95%CI：-8.8，-1.2；P=0.010，I²=0%，P=0.470）的降低幅度最大。
葡萄多酚通过显著降低LDL-C和oxLDL-C的血浆水平，对人体血脂谱产生有利影响。
